JAMA Dermatology Reports VALOR Skin Gains
2026-08-27
"Fifty‑four percent" is the quiet shock in the new VALOR report, as JAMA Dermatology now details how brepocitinib 30 mg reshaped skin outcomes in adults with dermatomyositis while muscle status sat in the background. In this Phase 3 study, the oral TYK2 and JAK1 inhibitor produced rapid and sustained gains across disease activity, itch, and skin‑related quality of life compared with placebo.
The headline claim is simple: skin moves first. Among patients who entered the trial with at least moderate itch, clinically meaningful improvement emerged by Week 4 in 54% of those on brepocitinib versus 10% on placebo, and that gap widened by Week 52 to 74% versus 33%. These differences tracked with changes in validated instruments, including the Itch Numeric Rating Scale and dermatology‑specific quality‑of‑life scores.
More disruptive is how close the data come to remission. In participants with moderate‑to‑severe skin disease at baseline, almost half of those receiving brepocitinib 30 mg reached near‑clearance thresholds by Week 52: 46% were rated "Clear" or "Almost Clear" on the Investigators Global Assessment, while 44% achieved functional skin remission on the Cutaneous Dermatomyositis Activity and Severity Index‑Activity Score. Placebo lagged at 22% and 21%, respectively, underscoring a more than two‑fold separation that now sits alongside previously reported muscle strength and steroid‑sparing benefits from the same VALOR trial in the New England Journal of Medicine.
What begins as a set of percentages ends as a redefinition of where dermatomyositis care might anchor its goals, with skin no longer an afterthought but a measurable, rapidly shifting front line.
Loading...
